Talilmogene Iaherparepvec generates systemic T-cell-mediated anti-tumor immunity by Julia Piasecki et al.
POSTER PRESENTATION Open Access
Talilmogene Iaherparepvec generates systemic
T-cell-mediated anti-tumor immunity
Julia Piasecki, Le Tiep, Jean Zhou, Courtney Beers*
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Talimogene laherparepvec is an investigational oncolytic
immunotherapy based on a modified herpes simplex virus
type-1 (HSV-1) that is designed to selectively replicate in
tumor tissue and to stimulate a systemic antitumor
immune response. Intralesional administration of talimo-
gene laherparepvec is intended to result in oncolysis
within injected tumors. Iterative viral replication of virus
within permissive tumor tissue results in lytic cell destruc-
tion and local release of progeny virus and cellular derived
antigens. GM-CSF, a product of the viral transgene, is also
produced locally such that it can recruit and stimulate
antigen presenting cells which, in addition to relevant
tumor-derived antigens, are required for the initiation of a
systemic antitumor immune response. A phase 3 clinical
trial of talimogene laherparepvec in regionally or distantly
metastatic melanoma has recently reported a 26% ORR
objective response rate (6% for GM-CSF alone){(J Clin
Oncol 31, 2013 (suppl; abstr LBA9008)}. Since the
immune mediated anti-tumor mechanisms have yet to be
fully understood, we sought to identify immune-specific
changes post talimogene laherparepvec administration in
the A20 syngeneic contralateral tumor model. We ana-
lyzed immune populations in both injected and non-
injected tumors and in peripheral hematopoietic tissues at
2, 5 and 10 days post injection. Animals received one
5x106 PFU intratumoral dose of talimogene laherparepvec
which induces complete regression in approximately
70-100% of the injected tumors and approximately 50-60%
of the contralateral non-injected tumors. Injection of virus
resulted in marked increases in injected tumor draining
lymph node and spleen size compared to control animals.
Upon further flow cytometric analysis, changes in T-cell
populations were observed in the injected and non-
injected tumor draining lymph nodes, spleen and periph-
eral blood and T-cells expressed higher levels of cell
surface activation markers as early as 2 days post-treatment
in talimogene laherparepvec treated animals as compared
to vehicle control animals. To functionally examine the
T-cell-mediated anti-tumor immunity, we evaluated the
memory response by re-challenging mice that completely
regressed their primary A20 tumors with either A20 or
three other Balb/c-derived tumor cell lines; 4T1, CT26 and
RENCA. Interestingly, the mice displayed broad immunity
to Balb/c tumor cells and rejected the A20, CT26 and
RENCA but not 4T1 tumor cells whereas all the tumor cell
lines grew robustly in control naïve animals. In addition,
splenic T-cells from talimogene laherparepvec-treated mice
induced A20 tumor cell killing ex vivo while T-cells from
vehicle control-treated mice did not. Intratumoral injection
of talimogene laherparepvec systemically activates
T cells and generates anti-tumor immunity in mice.
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